BACKGROUND AND OBJECTIVES BBR 2778 is a new aza-anthracenedione. Its activity against hematologic neoplasias in a mouse model is greater than that of doxorubicin or mitoxantrone. A phase-I study in patients with non-Hodgkin's lymphoma (NHL) showed that the drug has promising anti-tumor activity. Therefore, a phase-II study in patients with relapsed aggressive NHL was initiated. DESIGN AND

Контрактные б/у коробки передач (АКПП и МКПП) Chevrolet Chrysler Citroen Fiat Ford в Уфе. Компания Логист, ООО на BizOrg.su, ID 7213468.

BBR 2778. Pixantrone. BSA. Dec 12, 2018 (2003) Phase-II study of the new aza- anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Dec 19, 2018 Pixantrone (Pixuvri, BBR 2778) is a cytotoxic aza‐anthracenedione that directly alkylates DNA, forming stable DNA adducts and cross‐strand Oct 21, 2020 https://orcid.org/0000-0003-2778-0943. Print view. Open a version of this ORCID 2019-01 | journal-article. DOI: 10.1016/j.bbr.2018.08.034.

Bbr 2778

2500. › 9 - 12. 2135. 2669. › 9 - 13.

toxic potency lower than that of mitoxantrone and doxorubicin. BBR 2778 was more cy1otoxic in leukemia and lymphoma cell lines than in solid tumor cell lines.

av I Flodström · 1908 · Citerat av 1 — Det bbr ddirfbr undersbkas, om ej nagra lattnader pa ett eller annat 2778. 2573. 80 07. 4223. 25-19. 28-96. 207. 230. 30.39. 29'33. 27-74. 2515. 30 40. 25'41.

Underskrift av byggherre, efter färdigbyggt av I Flodström · 1908 · Citerat av 1 — Det bbr ddirfbr undersbkas, om ej nagra lattnader pa ett eller annat 2778. 2573.

Pixantrone is a synthetic, noncardiotoxic aza-anthracenedione analogue with potential antineoplastic activity. Pixantrone intercalates into DNA and induces topoisomerase II-mediated DNA strand crosslinks, resulting in inhibition of DNA replication and tumor cell cytotoxicity.

2779 JOSEF. CZERNY BBR EKONOMI AB LEGERINGSGATAN 5.

3,600. 1,163.
Din tur saldo

This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines (such as the tricyclic central quinoid chromophore). A novel aza-anthracenedione, pixantrone (BBR 2778), was developed to reduce treatment-related cardiotoxicity while retaining efficacy. This study evaluates the cumulative cardiotoxic potential of pixantrone compared with equiactive doses of doxorubicin and mitoxantrone in both doxorubicin-pretreated and doxorubicin-naïve mice. Background and objectives: BBR 2778 is a new aza-anthracenedione. Its activity against hematologic neoplasias in a mouse model is greater than that of doxorubicin or mitoxantrone.

2 golvbrädor. 0,1.
Examensordning lärarutbildning

klar och förfallen fordran
provoice holding ab
gymnasiematte 1c
svenska postnummer
good cop bad cop review
medical records clerk salary
vetenskapens

BBR 2778 (6,9 [bis (2-aminoethyl)-amino]-benzo [g] isoquinolone-5,10-dione dimaleate salt) is a novel heteroanalogue of anthracenediones ().The mechanism of action of BBR 2778 is similar to that of mitoxantrone in terms of DNA intercalation, DNA affinity, topoisomerase II interaction and formation of single strand breaks.

2515. 30 40.

Låna böcker i annan stad
svenska kurs stockholm gratis

Cavalletti E, et al. Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest New Drugs. 2007 Jun;25(3):187-95. [4]. Ubiali F, et al. Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats.

Purity of all the compounds was assured using NMR and TLC. The photoaffinity probe NHS-ASA was purchased from Pierce. The procedure used to synthesize photolabeled DEH and BBR 2778 is described in our recent report . Barrel 55 bbr, Brookville, Pennsylvania. 2.6K likes. American Restaurant creating made to order dishes, desserts and spirits.

Toxicological studies indicated that BBR 2778 was not cardiotoxic, and US patents are held by the University of Vermont.; Novuspharma, an Italian company, was established in 1998 following the merger of Boehringer Mannheim and Hoffmann-La Roche, and BBR 2778 was developed as Novuspharma's leading anti-cancer drug, pixantrone.

BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models. This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines (such as the tricyclic central quinoid chromophore). Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas These results indicate that 85 mg/m2 BBR 2778 in a q1w x 3 schedule is active in elderly and pretreated patients with relapsed aggressive NHL and was generally well tolerated. A novel aza-anthracenedione, pixantrone (BBR 2778), was developed to reduce treatment-related cardiotoxicity while retaining efficacy. This study evaluates the cumulative cardiotoxic potential of pixantrone compared with equiactive doses of doxorubicin and mitoxantrone in both doxorubicin-pretreated and doxorubicin-naïve mice. The anthracenedione analogue, BBR 2778 is an active antitumour agent preclinically and has reduced potential for cardiotoxicity compared with other similar drugs in preclinical models. BBR 2778 was administered 3 weekly by a 1 h intravenous (i.v.) infusion to 24 patients and the dose escalated rapidly from 20 to 240 mg/m2.

This rank Category termType chi_square shrOfCwithTerm shrOfTermInClass termInClass; 1: MITOXANTRONE: authKW: 624235: 13%: 15%: 146: 2: PIXANTRONE: authKW: 564995: 2%: 76% BBR 2778 is a novel aza-anthracenedione that has activity in experimental tumors and shows reduced potential for cardiotoxicity in animal models. This cytotoxic agent has structural similarities with mitoxantrone as well as general similarities with anthracyclines (such as the tricyclic central quinoid chromophore).